FABTECH TECHNOLOGIES LTD

Designs, manufactures and integrates process equipment, containment systems, cleanroom partitions and utilities for pharmaceutical manufacturing facilities in emerging markets, with in-house compliance to WHO, EU-GMP, USFDA and UKMHRA standards. FY26 consolidated revenue was ₹410.77 crore, with the largest shares from Rest of the World (31.6%), UAE (27.9%) and Saudi Arabia (18.2%); India contributed 10.0%, Kenya 9.6%, with smaller contributions from Egypt (1.4%) and Algeria (1.4%). The order book stood at over ₹900 crore, giving 18-24 months of execution visibility, alongside a hot-lead pipeline of ~$200 million USD. A ₹230 crore equity infusion lifted cash and bank balances 5x to ₹208.57 crore and cut debt from ₹54 crore to ₹42 crore, leaving the balance sheet net cash. The cost structure is dominated by other operating expenses at 21.9% of revenue and employee costs at 10.5%, with raw material cost flagged as a +33% headwind and execution cost a +43% headwind during the year. The business is project-based, dependent on capex cycles of pharma customers across MENA, Africa and India.